a group of researchers from Memorial Sloan Kettering Cancer Center reported in the journal Science Translational Medicine that a specific pattern, or “signature,” of markers on immune cells in the blood is a likely biomarker of response to checkpoint immunotherapy. Within this immune signature, a molecule LAG-3 provided key information identifying patients with poorer outcomes.
MSK Study Identifies Biomarker That May Help Predict Benefits of Immunotherapy
Source : https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy
In recent years, immune-based treatments for cancer have buoyed the hopes of doctors and patients alike. Drugs called immune checkpoint inhibitors have provided lifesaving benefits to a growing list of people with several types of cancer, including melanoma, lung cancer, bladder cancer, and many more.